文献速递肝病消化道肿瘤与早癌

HBV整合位点来源的游离病毒-宿主嵌合DNA作为肝细胞癌循环生物标志物

Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer.
PubMed 文献 · Hepatology · 2020-11-26

该研究探讨了HBV整合产生的病毒-宿主嵌合DNA(vh-DNA)作为HBV相关肝细胞癌(HCC)循环生物标志物的可行性。通过杂交捕获NGS确定50例患者HBV整合位点,并用ddPCR定量血浆vh-DNA。结果表明vh-DNA在97.7%的患者中可检测到,且术后2个月仍可检测到vh-DNA的患者中90%在1年内复发,有助于监测残留肿瘤和复发克隆性。

要点

  • vh-DNA在97.7%的HBV相关HCC患者血浆中可检测到,并与肿瘤大小相关。
  • 术后2个月血浆vh-DNA阳性提示残留肿瘤细胞,与早期复发独立相关。
  • 复发时分析vh-DNA有助于区分原克隆复发(81.8%)和新发HCC(18.2%)。

核心结论

  • vh-DNA可作为检测HBV相关HCC肿瘤负荷的循环生物标志物,并有助于监测术后残留肿瘤和复发克隆性。

研究设计与样本

  • 研究纳入50例HBV相关HCC患者,采用杂交捕获基NGS确定HBV整合位点,并用特异性ddPCR定量血浆vh-DNA。

主要发现

  • 44/50例患者中鉴定出HBV整合,43例(97.7%)基线血浆中检测到vh-DNA,其水平与肿瘤大小相关(检测限1.5 cm)。
  • 术后2个月血浆中,10例(23.3%)仍可检测到基线相同的vh-DNA,其中9例(90%)在1年内复发。
  • 复发时分析vh-DNA显示81.8%的复发来自原HCC克隆,18.2%为新发HCC。

临床怎么用

  • 对于HBV相关HCC患者,可通过ddPCR动态监测血浆vh-DNA,术后持续阳性提示残留肿瘤和早期复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Early recurrence of hepatocellular carcinoma (HCC) after surgical resection compromises patient survival. Timely detection of HCC recurrence and its clonality is required to implement salvage therapies appropriately. This study examined the feasibility of virus-host chimera DNA (vh-DNA), generated from junctions of hepatitis B virus (HBV) integration in the HCC chromosome, as a circulating biomarker for this clinical setting. APPROACH AND RESULTS: HBV integration in 50 patients with HBV-related HCC was determined by the Hybridization capture-based next-generation sequencing (NGS) platform. For individual HCC, the vh-DNA was quantified by specific droplet digital PCR (ddPCR) assay in plasma samples collected before and 2 months after surgery. HBV integrations were identified in 44 out of 50 patients with HBV-related HCC. Tumor-specific ddPCR was developed to measure the corresponding vh-DNA copy number in baseline plasma from each patient immediately before surgery. vh-DNA was detected in 43 patients (97.7%), and the levels correlated with the tumor sizes (detection limit at 1.5 cm). Among the plasma collected at 2 months after surgery, 10 cases (23.3%) still contained the same signature vh-DNA detected at baseline, indicating the presence of residual tumor cells. Nine of them (90%) experienced HCC recurrence within 1 year, supporting vh-DNA as an independent risk factor in predicting early recurrence. Analysis of circulating vh-DNA at recurrence further helped identify the clonal origin. A total of 81.8% of recurrences came from original HCC clones sharing the same plasma vh-DNA, whereas 18.2% were from de novo HCC. CONCLUSIONS: vh-DNA was shown to be a circulating biomarker for detecting the tumor load in majority of patients with HBV-related HCC and aided in monitoring residual tumor and recurrence clonality after tumor resection.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Li CL, Ho MC, Lin YY, et al. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. Hepatology. 2020. PMID: 32171027. doi:10.1002/hep.31230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。